Digital Marketing Trends in Rheumatoid Arthritis, 2022 Research Report Featuring AbbVie, Janssen, Eli Lilly, Amgen, UCB, Pfizer, Roche, Sanofi, & Regeneron – ResearchAndMarkets.com – Yahoo Finance

DUBLIN, May 05, 2022–(BUSINESS WIRE)–The "Digital Marketing Trends in Rheumatoid Arthritis" report has been added to ResearchAndMarkets.com's offering.
AbbVie's Humira.com achieved the highest total traffic across RA patient sites in the US, with 7.3 million visitors from February 2021 to January 2022, followed by Pfizer's Xeljanz.com and Amgen's Enbrel.com.
The highest proportion of traffic to branded patient RA websites originated from direct sources, followed by paid. Remicade.com and Simponi.com had the highest proportion of traffic from direct search, followed by Enbrel.com.
For patient branded sites, AbbVie spent the most on DDA for Humira.com at $4.9 million, followed by AbbVie's Rinvoq.com at $3.5 million, and Pfizer's Xeljanz.com at $2.1 million.
For HCP sites, AbbVie's Humirapro.com had the highest number of total visitors, totaling around 190,000 visits from February 2021 to January 2022. The highest proportion of traffic to HCP websites in the US originated from organic and direct sources. Actemrahcp.com had the highest proportion of traffic from organic searches, followed by Remicadehcp.com.
In the US, Genentech and Sanofi were the top companies using corporate social media channels to post RA-related content. AbbVie's branded Complete Medication Tracker app for Humira and Rinvoq had the highest downloads in 2021.
In EUCAN, AbbVie is a leading player with high traffic to its country-specific branded AbbVie Care sites, as well as Janssen with its Bioadvancemember.ca.
In EUCAN, AbbVie's Instagram account in Spain had the highest interaction for RA-related posts. There were few EUCAN mobile apps with notable activity in 2021, with Biogen's Care+ Italia app achieving the most downloads.
Scope
This report assesses key digital marketing metrics of pharma assets in rheumatoid arthritis (RA), including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts
Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads, and social media post interaction
Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN)
Reasons to Buy
Understand the digital marketing competitive landscape in RA, with a view of leading patient and HCP branded assets across different regions
See what tactics pharma companies are using to drive traffic to their RA branded assets for patient and HCPs, such as DDA and paid SEO
Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches
Compare top branded assets for patients by how they address and support different patient needs
See what pharma social media accounts in RA are the most active and achieving the most engagement
See leading mobile app offerings in RA from pharma across different regions
Key Topics Covered:
Executive Summary
US Patient Branded Websites
US Hcp Branded Websites
US Digital Display Advertising and Search Engine Optimization
US Mobile Apps and Social Media
Eucan Branded Websites
Eucan Mobile Apps and Social Media
Appendix
Companies Mentioned
AbbVie
Janssen
Eli Lilly
Amgen
UCB
Pfizer
Roche
Sanofi
Regeneron
For more information about this report visit https://www.researchandmarkets.com/r/sb65dq
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005602/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
It's a tech-astrophe out there. But you have options.
These snowbirds are heading south for the winter. And staying put.
Financial services giant Fidelity has a rule for retirement savings you may have heard of: Have 10 times your annual salary saved for retirement by age 67. This oft-cited guideline can help you identify a retirement savings goal, but it … Continue reading → The post Should the 45% Rule Guide Your Retirement Strategy? appeared first on SmartAsset Blog.
(Bloomberg) — Ken Griffin’s Citadel churned out a record $16 billion in profit for clients last year, outperforming the rest of the industry and one of history’s most successful financial plays.Most Read from BloombergPrince Andrew and Virginia Giuffre Photo Is Fake: Ghislaine MaxwellSuspect in Shooting Near Los Angeles Has Killed HimselfCitadel Makes $16 Billion to Top Paulson’s ‘Greatest Trade Ever’China Says Covid Deaths Top 12,600 and More Than 1 Billion InfectedHolmes Belongs in Prison, No
In this article, we will take a look at the 10 dirt cheap stocks to buy. To see more such companies, go directly to 5 Dirt Cheap Stocks To Buy. Amid a disastrous 2022 some analysts and market pundits are predicting a market rebound in late 2023 or 2024. Historically, market declines have given a […]
Tough times are coming — but that doesn't mean you can't make money.
In this article, we will take a look at the 13 biggest gold mines in the world. You can skip this part and go to 5 Biggest Gold Mines in the World. Investors almost always remain focused on the movement of gold, perhaps the most valuable and reliable asset in the world. Gold price touched […]
Dow Jones futures: Tech stocks are reviving, leading Friday's market rally. Tesla and Boeing headline market-moving earnings reports on tap.
The inflation-adjusted income thresholds for the seven tax brackets jumped by more than 7% from 2022.
By 15 years and a million miles, it’s not 2008.
If you keep money in a regular savings account you will generally owe federal income taxes on the interest that is earned. You'll pay taxes at your regular rate the year interest is earned, whether or not you withdraw from … Continue reading → The post How to Avoid Tax on a Savings Account appeared first on SmartAsset Blog.
Tesla recent price cuts on its most popular models in the U.S. are reverberating through the car business, pressuring rivals and affecting purchase decisions for new- and used-car buyers. The Elon Musk -led car maker’s most recent cut—slashing as much as 20% from the price of some versions of its top-selling Model Y earlier this month—shocked Stanly Tran. “‘There’s no way,’” Mr. Tran recalls thinking when he saw Tesla’s new prices.
Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Tesla Inc. is rated Hold with a C rating by TheStreet's Quant Ratings.
These supercharged income stocks, with an average yield of 10.06%, can generate $1,000 in annual income with an initial investment of less than $10,000.
ExxonMobil (NYSE: XOM) is one of the largest integrated oil and gas companies on earth. And after more than a decade of poor returns, it's become a lean, mean cash-flow-generating machine. But it didn't come easy, and management has a secret weapon to boost returns for investors.
These best-of-breed names belong to a select group of 48 companies that have raised their dividends for at least 50 consecutive years.
Intel (NASDAQ: INTC) provided investors with insights into what it's thinking about its future business prospects. This video captures the critical moments from that update. *Stock prices used were the afternoon prices of Jan.
DNB Asset Management increased positions in Tesla and Plug Power, while slashing its stake in General Motors in the fourth quarter.
If you want $10,000 in passive income in 2023, it's possible to do so by investing a total of $110,000 in these high-yield dividend stocks. As a BDC, Ares provides financing to small to medium-sized businesses. The company must return at least 90% of its taxable income to shareholders in the form of dividends.
The government is in a doom spiral of spending and borrowing

source

Leave a Comment